|Bid||1.1400 x 900|
|Ask||1.2700 x 800|
|Day's Range||1.1800 - 1.2700|
|52 Week Range||0.5770 - 8.8000|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2023 - Mar 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. It is currently in Phase 1 development for solid tumors. Jounce will recei